{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/prescribing-information/thiazide-type-diuretics/","result":{"pageContext":{"chapter":{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics","depth":2,"htmlHeader":"<!-- begin field 48d4802f-6e02-49c1-84ec-a71600db29e7 --><h2>Thiazide-type diuretics</h2><!-- end field 48d4802f-6e02-49c1-84ec-a71600db29e7 -->","summary":"","htmlStringContent":"<!-- begin item 39e73b93-050a-489a-9220-a71600db2a87 --><!-- end item 39e73b93-050a-489a-9220-a71600db2a87 -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"82b84677-7655-5980-a70f-bc6cf90e2579","slug":"choice-of-thiazide-type-diuretic","fullItemName":"Choice of thiazide-type diuretic","depth":3,"htmlHeader":"<!-- begin field 4022415a-500c-43fa-971d-a71a00ccacd5 --><h3>Which thiazide-type diuretic should I use?</h3><!-- end field 4022415a-500c-43fa-971d-a71a00ccacd5 -->","summary":"","htmlStringContent":"<!-- begin item 45ab9d80-7f25-4711-91d9-a71a00ccad9e --><!-- begin field 733c29a8-fa8d-4e5f-8523-a71a00ccacd5 --><ul><li>The choice of thiazide-type diuretic usually depends on the person's co-morbidities, local recommendations, and cost.</li><li>Where possible, prescribe a drug that is taken only once a day and prescribe non-proprietary drugs where these are appropriate and minimise cost.</li><li>If a person is already taking a conventional thiazide diuretic such as bendroflumethiazide, and their blood pressure is well controlled, continue this treatment.<ul><li>If a thiazide-type diuretic is to be started or changed, indapamide or chlortalidone may be preferred over bendroflumethiazide.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">National Clinical Guideline Centre, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>] </p><!-- end field 733c29a8-fa8d-4e5f-8523-a71a00ccacd5 --><!-- end item 45ab9d80-7f25-4711-91d9-a71a00ccad9e -->","subChapters":[]},{"id":"5c6dbcf7-4cce-50da-8ea1-97a7cb848855","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ca2389e3-2a15-433b-ad6a-a71a00ccc4ef --><h3>Contraindications and cautions</h3><!-- end field ca2389e3-2a15-433b-ad6a-a71a00ccc4ef -->","summary":"","htmlStringContent":"<!-- begin item 3fd43025-3ae6-4fc0-acfb-a71a00ccc646 --><!-- begin field 338ca471-4d66-459f-853f-a71a00ccc4ef --><ul><li><strong>Thiazide-type diuretics should be avoided in:</strong><ul><li>People with:<ul><li>Refractory hypokalaemia.</li><li>Hyponatraemia.</li><li>Hypercalcaemia. </li><li>Addison's disease. </li><li>Asymptomatic hyperuricaemia.</li><li>Severe liver disease.</li><li>eGFR of less than 30 mL/minute/1.73 m<sup>2 </sup>— due to lack of efficacy.</li></ul></li><li>Pregnant women — due to risk of neonatal thrombocytopenia, bone marrow suppression, jaundice, electrolyte disturbance, hypoglycaemia, and reduced placental perfusion.</li></ul></li><li><strong>Thiazide-type diuretics should be prescribed with caution in people with:</strong><ul><li>Diabetes, gout, and systemic lupus erythematosus — due to risk of exacerbation of these conditions.</li><li>Hyperaldosteronism.</li><li>Malnourishment.</li><li>Nephrotic syndrome.</li><li>Severe cardiovascular disease, or who are being treated with cardiac glycosides — due to the danger posed by hypokalaemia in these people.</li><li>Mild to moderate hepatic impairment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 338ca471-4d66-459f-853f-a71a00ccc4ef --><!-- end item 3fd43025-3ae6-4fc0-acfb-a71a00ccc646 -->","subChapters":[]},{"id":"6315c353-0cdc-565a-8c4f-3ad0c428e508","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 33457acf-6d1d-47f7-bfc4-a71a00cd1c0d --><h3>Adverse effects</h3><!-- end field 33457acf-6d1d-47f7-bfc4-a71a00cd1c0d -->","summary":"","htmlStringContent":"<!-- begin item 825b6342-9911-4657-901c-a71a00cd1c6d --><!-- begin field eb11b4f0-d977-4856-8c28-a71a00cd1c0d --><ul><li><strong>Adverse effects of thiazide-type diuretics include:</strong><ul><li>Postural hypotension.</li><li>Hyperglycaemia.</li><li>Hypokalaemia.</li><li>Other electrolyte imbalances — hyponatraemia, hypomagnesaemia, hypercalcaemia have also been noted.<ul><li>Electrolytes should be monitored, particularly with high doses and long-term use, and in people with renal impairment.</li></ul></li><li>Hypochloremic alkalosis.</li><li>Mild gastrointestinal disturbances.</li><li>Altered plasma-lipid concentrations.</li><li>Cardiac arrhythmias.</li><li>Dizziness and headache.</li><li>Choroidal effusion, acute transient myopia and acute secondary angle-closure glaucoma.</li><li>Erectile dysfunction.</li></ul></li><li><strong>Note: </strong>elderly people may particularly susceptible to the adverse effects of thiazide-type diuretics.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2020b</a>]</p><!-- end field eb11b4f0-d977-4856-8c28-a71a00cd1c0d --><!-- end item 825b6342-9911-4657-901c-a71a00cd1c6d -->","subChapters":[]},{"id":"e9c508fc-4aee-5126-8cff-1d782e441ed6","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 087ab159-a6b5-4bc8-8c8f-a78800c81fba --><h3>Drug interactions</h3><!-- end field 087ab159-a6b5-4bc8-8c8f-a78800c81fba -->","summary":"","htmlStringContent":"<!-- begin item 1cd8ab87-189b-40a1-b825-a78800c81280 --><!-- begin field 50c7c8c3-7500-4de7-a859-a78800c81fba --><p><strong>Drug interactions with thiazide-type diuretics include:</strong></p><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs)</strong> — ACE inhibitors and ARBs can cause a very rapid fall in blood pressure in a person who is volume-depleted.<ul><li>If the dose of diuretic is greater than 80 mg furosemide or equivalent, the ACE inhibitor or ARB should be initiated under close supervision and in some cases, the diuretic dose may need to be reduced, or the diuretic discontinued at least 24 hours beforehand.</li><li>If high dose diuretic therapy cannot be stopped, close observation is recommended for at least 2 hours following the first dose of ACE inhibitor/ARB, or until the blood pressure has stabilised.</li></ul></li><li><strong>Alpha-blockers</strong> — enhanced hypotensive effect and increased risk of first-dose hypotension.</li><li><strong>Amisulpride, atomoxetine, pimozide</strong> — increased risk of ventricular arrhythmias.</li><li><strong>Aminophylline, reboxetine</strong> — increased risk of hypokalaemia. Monitoring of electrolytes and renal function may be advised.</li><li><strong>NSAIDs</strong> — increased risk of nephrotoxicity and antagonism of diuretic effect with concomitant use.</li><li><strong>Amiodarone, disopyramide, flecainide</strong> — hypokalaemia caused by thiazide diuretics increases the risk of cardiac toxicity of these drugs.</li><li><strong>Rifampicin, lymecycline </strong>— concurrent use not advised by manufacturers</li><li><strong>Aminoglycosides</strong> — increased risk of ototoxicity.</li><li><strong>Tricyclic antidepressants</strong> — increased risk of postural hypotension.</li><li><strong>Aldesleukin, alprostadil, anxiolytics, baclofen, beta-blockers, calcium channel blockers, clonidine, co-beneldopa, co-careldopa, hydralazine, hypnotics, levodopa, MAOIs, methyldopa, minoxidil, moxonidine, nitrates, phenothiazines, sodium nitroprusside, tizanidine</strong> — enhanced hypotensive effect.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 50c7c8c3-7500-4de7-a859-a78800c81fba --><!-- end item 1cd8ab87-189b-40a1-b825-a78800c81280 -->","subChapters":[]},{"id":"45c45619-0863-5c3e-9fcc-4b5bafc7df3e","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 4a72ad31-cfe5-492f-a371-a71a00ccd76a --><h3>Dose and titration</h3><!-- end field 4a72ad31-cfe5-492f-a371-a71a00ccd76a -->","summary":"","htmlStringContent":"<!-- begin item b47d9929-b1de-4872-a7ec-a71a00ccd83e --><!-- begin field 3e802ec9-2a88-443b-ab2b-a71a00ccd76a --><ul><li><strong>Chlortalidone:</strong><ul><li>Starting dose is 25 mg daily, to be taken in the morning.</li><li>Increase up to 50 mg daily if necessary.</li></ul></li><li><strong>Indapamide:</strong><ul><li>Dose is 2.5 mg daily, to be taken in the morning.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>] </p><!-- end field 3e802ec9-2a88-443b-ab2b-a71a00ccd76a --><!-- end item b47d9929-b1de-4872-a7ec-a71a00ccd83e -->","subChapters":[]},{"id":"283e37c0-b7d6-563c-9828-fd4d11633b24","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 9dc40351-455c-4838-b827-a78c009aa086 --><h3>Monitoring</h3><!-- end field 9dc40351-455c-4838-b827-a78c009aa086 -->","summary":"","htmlStringContent":"<!-- begin item 4a0c7b91-303f-46fe-9b0d-a78c009a98ef --><!-- begin field 1721d4e5-8fc3-4929-aedf-a78c009aa086 --><ul><li><strong>Plasma sodium levels</strong> should be measured before starting treatment, then at regular intervals subsequently, depending on clinical judgement. <ul><li>Monitoring should be more frequent in elderly people and those with cirrhosis.<ul><li>A fall in plasma sodium may be asymptomatic initially and regular monitoring is therefore essential.</li></ul></li></ul></li><li><strong>Plasma potassium levels</strong> should be monitored prior to initiation of treatment and regularly during treatment, including during the first week. <ul><li>More frequent monitoring of plasma potassium is required in people who are elderly, malnourished, polymedicated, with cirrhosis, oedema and ascites, coronary artery disease, a long QT interval, and/or cardiac failure.  Hypokalaemia (< 3.4 mmol/l) must be prevented in these groups as it increases the cardiac toxicity of digitalis preparations and the risk of arrhythmias.</li></ul></li><li><strong>Monitoring of renal and liver function before initiation of treatment should be considered.</strong><ul><li>Thiazide-type diuretics are ineffective if eGFR is less than 30 mL/minute/1.73m<sup>2</sup>, and are contraindicated in people with severe renal failure.</li><li>They are contraindicated in people with severe impairment of liver function and should be used with caution in people with impaired hepatic function or progressive liver disease, since minor changes in fluid and electrolyte balance may precipitate hepatic coma.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 1721d4e5-8fc3-4929-aedf-a78c009aa086 --><!-- end item 4a0c7b91-303f-46fe-9b0d-a78c009a98ef -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}